NCT05897099 Comprehensive HIV and Harm Prevention Via Telehealth
| NCT ID | NCT05897099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 350 participants |
| Start Date | 2024-10-07 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 350 participants in total. It began in 2024-10-07 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to test 2 different ways to offer medications to prevent human immunodeficiency virus (HIV), cure hepatitis C virus (HCV) (if applicable) and treat substance use disorder (if desired) in people who inject drugs.
Eligibility Criteria
Inclusion Criteria: * age 18 or older * able to speak English or Spanish * willing and able to sign informed consent, provide locator information and medical records release * non-reactive result on rapid HIV test * use of SSP to exchange syringes 2 times in the past 3 months * planning to stay in the area for 12 months Exclusion Criteria: * reactive HIV test * currently on medications for opioid use disorder (MOUD) by urine drug screen * currently on PrEP by self-report * Principal or site investigator discretion * currently in prison or jail * current enrollment in Clinical Trials Network 121 * receipt of tele-harm reduction in previous 3 months * signs or symptoms of acute HIV infection
Contact & Investigator
Hansel Tookes, MD
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT05897099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05897099 currently recruiting?
Yes, NCT05897099 is actively recruiting participants. Contact the research team at hetookes@med.miami.edu for enrollment information.
Where is the NCT05897099 trial being conducted?
This trial is being conducted at Miami, United States, Miami, United States.
Who is sponsoring the NCT05897099 clinical trial?
NCT05897099 is sponsored by University of Miami. The principal investigator is Hansel Tookes, MD at University of Miami. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.